• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

New CDC Interim Guidance on Infants with Possible Zika & Perinatal Review (Oct 2017)

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. List the key clinical findings in infants with Zika infection
2. Discuss the role of ultrasound in prenatal monitoring of fetuses who may be infected with Zika virus
3. Incorporate the latest guidelines when managing an infant who may be infected with Zika Virus
4. Recall the change in newborn hearing screening for children potentially infected with Zika virus

Estimated time to complete activity: 0.5 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 1/31/2017 through 1/25/2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Read Disclaimer & Fine Print

SUMMARY:

On October 20th, the CDC released interim guidance for the diagnosis and management of infants with possible congenital Zika infection.  According to the guidance document,

All infants born to mothers with possible Zika virus exposure during pregnancy should receive a standard evaluation at birth and at each subsequent well-child visit including a comprehensive physical examination, age-appropriate vision screening and developmental monitoring and screening using validated tools and newborn hearing screen at birth, preferably using auditory brainstem response (ABR) methodology.

Jump to:

  • Zika testing in pregnancy
  • Prenatal diagnosis & Zika
  • Congenital Zika – clinical findings
  • Infant findings present
    • Possible maternal exposure
  • No infant findings
    • Positive maternal labs
    • No maternal labs, possible maternal exposure

Definitions

  • Possible Zika virus exposure
    • Includes travel to, or residence in an area with mosquito borne Zika virus transmission OR
    • Sex without the use of condoms with a partner who has traveled to or resides in an area with mosquito borne Zika virus transmission 
  • Laboratory evidence of possible Zika virus infection during pregnancy: Defined as  
    • NAT: Zika virus infection detected by a Zika virus NAT on any maternal, placental, or fetal specimen (referred to as NAT-confirmed OR 
    • Serology: Positive/equivocal Zika virus IgM and Zika virus plaque reduction neutralization test (PRNT) titer ≥10, regardless of dengue virus PRNT value or negative Zika virus IgM, and positive or equivocal dengue virus IgM, and Zika virus PRNT titer ≥10, regardless of dengue virus PRNT titer 
    • Note: The use of PRNT for confirmation of Zika virus infection, including in pregnant women, is not routinely recommended in Puerto Rico
  • Assessment of visual acuity: Responses to teller or grating tests (if possible), pupillary response, external examination, anterior segment examination, intraocular pressure measurement if indicated, and dilated fundus examination 
    • After 3–4 months of age, also assess ocular motility, cycloplegia refraction and accommodation by dynamic retinoscopy 
    • If physical abnormalities are present, recommend photo documentation if resources are available

Updated Guidance for Testing of Pregnant Women with Possible Zika Virus Exposure  

  • Zika virus NAT testing should be offered as part of routine obstetric care to asymptomatic pregnant women with ongoing possible Zika virus exposure (residing in or frequently traveling to an area with risk for Zika virus transmission) 
  • Serologic testing is no longer routinely recommended because of the limitations of IgM tests  
  • Zika virus testing is not routinely recommended for asymptomatic pregnant women who have possible recent, but not ongoing, Zika virus exposure (however, guidance might vary among jurisdictions)  
  • Communication regarding possible maternal exposures between pediatric health care providers and obstetric care providers is critical 
  • For families of infants with possible congenital Zika virus infection health care providers should  
    • Ensure that psychosocial support is in place and that families have access to care 
    • Communicate that the long-term prognosis for infants with congenital Zika virus infection is not yet known 
    • Address families’ concerns, facilitate early identification of abnormal findings, and refer infants for neurodevelopmental follow-up and therapy when indicated

Special Considerations for the Prenatal Diagnosis of Congenital Zika Virus Infection

Ultrasound

  • Routine screening for fetal abnormalities is a component of prenatal care in the United States 
    • Comprehensive ultrasound examination to evaluate fetal anatomy is recommended for all women at 18–22 weeks’ gestation
    • If maternal testing does not suggest infection, patients should receive the same ultrasound screening as any other pregnant woman as part of standard routine prenatal care 
  • Prenatal ultrasound findings associated with congenital Zika virus infection include  
    • Intracranial calcifications at the gray-white matter junction 
    • Ventriculomegaly 
    • Abnormalities of the corpus callosum 
    • Microcephaly 
    • Limb anomalies  
  • Sensitivity, specificity, NPV and PPV of ultrasound findings for Zika virus unknown at this time  
  • Abnormalities have been detected anywhere from 2 to 29 weeks after symptom onset  
  • Brain abnormalities associated with congenital Zika syndrome have been identified by ultrasound in the second and third trimesters in published case reports  
  • Serial Ultrasound Monitoring  
    • CDC previously recommended serial ultrasounds every 3–4 weeks for women exposed during pregnancy with laboratory evidence of Zika virus infection 
    • No data specific to congenital Zika virus infection to guide these timing recommendations  
      • Clinicians may consider extending the time interval between ultrasounds in accordance with patient preferences and clinical judgment  
    • Women with possible exposure but without laboratory evidence of Zika virus infection during pregnancy should receive ultrasound screening as recommended for routine prenatal care 

Amniocentesis

  • The role of amniocentesis for the detection of congenital Zika virus infection is unknown 
  • PPV, NPV and optimal timing are unknown  
  • Positive Zika test results in amniotic fluid  
    • Zika virus RNA has been detected in amniotic fluid specimens 
    • Serial amniocenteses have demonstrated that Zika virus RNA might only be present transiently 
    • A negative test result on amniotic fluid cannot rule out congenital Zika virus infection 
    • If amniocentesis is indicated as part of the evaluation for abnormal prenatal findings, NAT testing for Zika virus should be considered to assist with the diagnosis of fetal infection 

Summary of prenatal diagnosis of congenital Zika virus infection

  • A shared decision-making model is essential to ensure that pregnant women and their families understand the risks and benefits of screening in the context of the patient’s preferences and values 
  • Decisions should be individualized 

Congenital Zika Virus Infection

  • Microcephaly  
  • Brain anomalies 
    • Thin cerebral cortices with enlarged ventricles and increased extra-axial fluid collections 
    • Intracranial calcifications  
    • Absent or hypoplastic corpus callosum 
    • Hypoplasia of the cerebellum or cerebellar vermis 
    • Hypoplasia of the ventral cord  
  • Eye anomalies (both anterior and posterior) 
    • Microphthalmia 
    • Coloboma 
    • Intraocular calcifications 
    • Optic nerve hypoplasia and atrophy 
    • Macular scarring with focal pigmentary retinal mottling
    • Even in absence of structural eye lesions, cortical visual impairment may be present due to anomalies in visual system of the brain  
  • Other neurologic sequelae  
    • Congenital limb contractures, dysphagia, sensorineural hearing loss, epilepsy, and abnormalities of tone or movement, including marked hypertonia and signs of extrapyramidal involvement  
  • Additional findings since last update 
    • Eye findings in infants without microcephaly or other brain anomalies  
    • Postnatal-onset microcephaly in infants born with normal head circumferences 
    • Postnatal-onset hydrocephalus in infants born with microcephaly
    • Abnormalities on sleep electroencephalogram (EEG) in some infants with microcephaly who did not have recognized seizures
    • Diaphragmatic paralysis in infants born with microcephaly and arthrogryposis 

Infants with Clinical Findings Consistent with Congenital Zika Syndrome and Mothers with Possible Zika Virus Exposure in Pregnancy

  • Laboratory Testing 
    • Zika virus testing is recommended, regardless of maternal testing results 
    • Testing CSF for Zika virus RNA and Zika virus IgM antibodies should be considered, especially if serum and urine testing are negative and another etiology has not been identified 
  • Clinical Evaluation and Management in addition to standard evaluation 
    • 1 month 
      • Head ultrasound 
      • Comprehensive ophthalmologic exam 
      • Automated ABR if the newborn hearing screen was passed using only otoacoustic emissions methodology  
    • Referral to a developmental specialist and early intervention service programs are recommended 
    • Consider the following referrals  
      • Infectious disease  
      • Clinical genetics for confirmation of the clinical phenotype and evaluation for other causes of microcephaly or congenital anomalies 
      • Neurology by age 1 month  
      • Other consultations based on clinical findings 
    • Note change from previous guidance: Diagnostic ABR is no longer recommended at age 4–6 months for infants who passed the initial hearing screen with automated ABR because of the absence of data suggesting delayed-onset hearing loss in infants with congenital Zika virus infection 

Infants without Clinical Findings Consistent with Congenital Zika Syndrome and Mothers with Laboratory Evidence of Possible Zika Virus Infection During Pregnancy

  • Laboratory Testing 
    • Zika virus testing is recommended
  • Clinical Evaluation and Management in addition to standard evaluation 
    • 1 month 
      • Head ultrasound 
      • Comprehensive ophthalmologic exam 
      • Automated ABR if the newborn hearing screen was passed using only otoacoustic emissions methodology  
    • Health care providers should perform  
      • Standard evaluation along with routine preventive pediatric care and immunizations at each subsequent well-child visit 
      • Remain vigilant for signs that might be associated with congenital Zika virus infection 
      • Refer if suspicious findings identified at any time 
  • Infants with Laboratory Evidence of Congenital Zika Virus Infection 
    • Laboratory evidence of congenital Zika virus infection includes  
      • Positive Zika virus NAT or  
      • A nonnegative Zika virus IgM with confirmatory neutralizing antibody testing, if PRNT confirmation is performed 
    • Follow recommendations for infants with clinical findings even in the absence of clinically apparent abnormalities 
  • Infants without laboratory evidence of congenital Zika virus infection 
    • If laboratory and clinical findings are both negative, infection is unlikely  
    • Infants should continue to receive routine pediatric care, and health care providers should remain alert for any new findings 

Infants without Clinical Findings Consistent with Congenital Zika Syndrome and Mothers with Possible Zika Virus Exposure in Pregnancy but No Laboratory Evidence

  • This category refers to mothers who were never tested or results could be negative related to timing or test related issues  
  • Laboratory Testing 
    • Not routinely recommended for infants born to mothers in this category  
    • If abnormal findings are identified, these infants should receive further evaluation, including evaluation and testing for congenital Zika virus infection 
  • Clinical Evaluation and Management 
    • Infants should have a standard evaluation performed at birth and at each subsequent well-child visit along with routine preventive pediatric care and immunizations 
    • Further clinical evaluation for congenital Zika virus infection beyond a standard evaluation and routine pediatric care is not routinely indicated 
    • Health care providers can consider additional evaluation in consultation with families, including
      • possible risks of screening (e.g., identification of incidental findings)
      • Maternal factors, such as the presence and timing of symptoms
      • Type, location, and length of possible Zika virus exposure 
    • Older infants in whom maternal Zika virus exposure was not assessed at birth and who are evaluated later might also have more clinical data  
    • If findings consistent with congenital Zika syndrome are identified at any time, referral as needed consistent with recommendations above for children with suspected Zika virus 

Learn More – Primary Sources:

Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection — United States, October 2017

ACOG Committee Opinion 784: Management of Patients in the Context of Zika Virus

Take a post-test and get CME credits

TAKE THE POST TEST

image_pdfFavoriteLoadingFavorite

< Previous
All Alerts Posts
Next >

Related ObG Topics:

CDC Guidance on Zika and Pregnancy
Practical obstetrics info for your women's healthcare practice
Microcephaly – Beyond the Zika Virus
Zika virus: transmission, symptoms and management
Zika Virus Disease: How to Counsel Your Patient About Prevention
CDC Guidance for Non-Pregnant Patients and Available Diagnostic Tests for Zika Virus

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site